Pharvaris Nv stock is traded at $34.33, with a volume of 309,426. It is down -1.29% in the last 24 hours and up +10.07% over the past month. Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
Previous Close:
$34.78
Open:
$35.06
24h Volume:
309,426
Relative Volume:
0.53
Market Cap:
$2.41B
Revenue:
-
Net Income/Loss:
-$195.21M
P/E Ratio:
-
EPS:
-$3.18
Net Cash Flow:
-$176.19M
1W Performance:
+4.60%
1M Performance:
+10.07%
6M Performance:
+14.36%
1Y Performance:
+58.64%
1-Day Range:
$33.03$35.42
1-Week Range:
$32.90$35.42
52-Week Range:
$21.02$43.25
Pharvaris Nv Stock (PHVS) Company Profile
Market Cap
Revenue
Net Income
Cash Flow
EPS